About the Authors

Ulrich Deuschle, Andreas Schulz, Thomas Schlüter, Olaf Kinzel, Claus Kremoser
Department of Research, Phenex Pharmaceuticals AG, Heidelberg, Germany

Julia Schüler
Department of In Vivo Tumor Biology, Oncotest GmbH, Freiburg, Germany

Ulrich Abel
Department of Medicinal Chemistry, Merz Pharmaceuticals GmbH, Frankfurt, Germany

Corresponding Author

ulrich.deuschle@phenex-pharma.com

Competing Interests

UA is a full-time employee of Merz Pharmaceuticals GmbH, JS is a full-time employee of Oncotest GmbH and the rest of the authors are full-time employees of Phenex Pharmaceuticals AG. UD and CK are co-founders of Phenex Pharmaceuticals AG and UD, AS and CK do own shares of Phenex Pharmaceuticals AG. Kremoser C, Abel U, Steeneck C, Kinzel O (2011) Patent Application WO2011/020615 Novel FXR (NR1H4) binding and activity modulating compounds. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: UD JS AS TS. Performed the experiments: UD AS TS. Analyzed the data: UD JS AS TS. Contributed reagents/materials/analysis tools: UD AS UA OK. Wrote the paper: UD CK.